Juno Therapeutics (JUNO) Posts Q4 Loss of $1.61/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
Go back to Juno Therapeutics (JUNO) Posts Q4 Loss of $1.61/Share
March 18, 2015 4:02 PM EDT
Conference call to be held on Wednesday, March 18, 2015 at 5:00 p.m. Eastern Time
Positive momentum and progress on clinical trials continues
Strong year-end cash position of $474.1 million
2015 cash burn guidance of $125 million to $150 million, excluding cash inflows or outflows from business development activities and ongoing litigation
SEATTLE, March 18, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today reported business highlights and financial... More
March 18, 2015 4:02 PM EDT
Conference call to be held on Wednesday, March 18, 2015 at 5:00 p.m. Eastern Time
Positive momentum and progress on clinical trials continues
Strong year-end cash position of $474.1 million
2015 cash burn guidance of $125 million to $150 million, excluding cash inflows or outflows from business development activities and ongoing litigation
SEATTLE, March 18, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today reported business highlights and financial... More
